Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AEGON LTD. Regulatory Filings 2016

May 12, 2016

30489_ffr_2016-05-12_b1c683ca-2c0d-4add-9995-9a541a500e46.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

6-K 1 d185599d6k.htm 6-K 6-K

Table of Contents

Securities and Exchange Commission

Washington, D.C. 20549

Form 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 of 15d/16

of the Securities Exchange Act of 1934

May 2016

AEGON N.V.

Aegonplein 50

2591 TV THE HAGUE

The Netherlands

Table of Contents

Aegon’s condensed consolidated interim financial statements Q1 2016, dated May 12, 2016, are included as appendix and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AEGON N.V.
(Registrant)
Date: May 12, 2016 By /s/ J.H.P.M. van Rossum
Executive Vice President and
Corporate Controller

Table of Contents

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 1

Table of contents

Condensed consolidated income statement 2
Condensed consolidated statement of comprehensive income 3
Condensed consolidated statement of financial position 4
Condensed consolidated statement of changes in equity 5
Condensed consolidated cash flow statement 6
Notes to the condensed consolidated interim financial statements 7

Unaudited

Table of Contents

2 Condensed Consolidated Interim Financial Statements Q1 2016

Condensed consolidated income statement — EUR millions Notes Q1 2016 Q1 2015
Premium income 4 5,836 6,347
Investment income 5 1,935 2,098
Fee and commission income 602 582
Other revenues 1 2
Total revenues 8,374 9,028
Income from reinsurance ceded 720 686
Results from financial transactions 6 2,050 9,905
Total income 11,146 19,618
Benefits and expenses 7 10,901 19,127
Impairment charges / (reversals) 8 40 13
Interest charges and related fees 97 108
Other charges - 11
Total charges 11,039 19,258
Share in net result of joint ventures 31 29
Income / (loss) before tax 138 389
Income tax (expense) / benefit 6 (100 )
Net income / (loss) 143 289
Net income / (loss) attributable to:
Equity holders of Aegon N.V. 143 289
Non-controlling interests - -
Earnings per share (EUR per share) 15
Basic earnings per common share 0.05 0.12
Basic earnings per common share B - -
Diluted earnings per common share 0.05 0.12
Diluted earnings per common share
B - -

Amounts for 2015 have been restated for the voluntary changes in accounting policies for deferred cost of reinsurance and insurance accounting in the UK. Refer to note 2.1 Voluntary changes in accounting policies for details about these changes.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 3

Condensed consolidated statement of comprehensive income — EUR millions Q1 2016 Q1 2015
Net income / (loss) 143 289
Other comprehensive income:
Items that will not be reclassified to profit or loss:
Changes in revaluation reserve real estate held for own use (2 ) 5
Remeasurements of defined benefit plans (501 ) (627 )
Income tax relating to items that will not be reclassified 135 159
Items that may be reclassified subsequently to profit or
loss:
Gains / (losses) on revaluation of available-for-sale investments 1,841 1,595
(Gains) / losses transferred to the income statement on disposal and impairment of
available-for-sale investments (30 ) (132 )
Changes in cash flow hedging reserve 304 558
Movement in foreign currency translation and net foreign investment hedging
reserve (734 ) 1,718
Equity movements of joint ventures 3 3
Equity movements of associates 1 -
Income tax relating to items that may be reclassified (762 ) (450 )
Other 6 3
Other comprehensive income for the period 261 2,831
Total comprehensive income /
(loss) 405 3,120
Total comprehensive income / (loss) attributable to:
Equity holders of Aegon N.V. 398 3,119
Non-controlling interests 7 -

Amounts for 2015 have been restated for the voluntary changes in accounting policies for deferred cost of reinsurance and insurance accounting in the UK. Refer to note 2.1 Voluntary changes in accounting policies for details about these changes.

Unaudited

Table of Contents

4 Condensed Consolidated Interim Financial Statements Q1 2016

| Condensed
consolidated statement of financial position | Mar. 31, 2016 | Dec. 31, 2015 | |
| --- | --- | --- | --- |
| EUR millions | Notes | | |
| Assets | | | |
| Intangible assets | 9 | 1,815 | 1,901 |
| Investments | 10 | 162,784 | 160,792 |
| Investments for account of policyholders | 11 | 191,286 | 200,226 |
| Derivatives | 12 | 17,288 | 11,545 |
| Investments in joint ventures | | 1,558 | 1,561 |
| Investments in associates | | 252 | 242 |
| Reinsurance assets | | 10,588 | 11,257 |
| Deferred expenses | 14 | 10,299 | 10,997 |
| Other assets and receivables | | 8,117 | 7,615 |
| Cash and cash equivalents | | 10,616 | 9,594 |
| Total assets | | 414,602 | 415,729 |
| Equity and liabilities | | | |
| Shareholders’ equity | | 22,848 | 22,684 |
| Other equity instruments | | 3,811 | 3,800 |
| Issued capital and reserves attributable to equity holders of Aegon
N.V. | | 26,659 | 26,485 |
| Non-controlling interests | | 16 | 9 |
| Group equity | | 26,674 | 26,494 |
| Trust pass-through securities | | 153 | 157 |
| Subordinated borrowings | | 757 | 759 |
| Insurance contracts | | 122,099 | 123,042 |
| Insurance contracts for account of policyholders | | 108,736 | 112,679 |
| Investment contracts | | 18,010 | 17,718 |
| Investment contracts for account of policyholders | | 85,321 | 90,119 |
| Derivatives | 12 | 16,468 | 10,890 |
| Borrowings | 16 | 10,806 | 12,445 |
| Other liabilities | | 25,577 | 21,427 |
| Total
liabilities | | 387,928 | 389,236 |
| Total equity and
liabilities | | 414,602 | 415,729 |

Amounts for 2015 have been restated for the voluntary changes in accounting policies for deferred cost of reinsurance and insurance accounting in the UK. Refer to note 2.1 Voluntary changes in accounting policies for details about these changes.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 5

| Condensed
consolidated statement of changes in equity — EUR millions | Share capital 1 | Retained earnings | Revaluation reserves | | Remeasurement of defined benefit plans | | Other reserves | | Other equity instruments | | Issued capital and reserves 2 | | Non- controlling interests | Total | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Three months ended March 31, 2016 | | | | | | | | | | | | | | | | |
| At beginning of year | 8,387 | 8,075 | | 6,471 | | (1,532 | ) | 1,283 | | 3,800 | | 26,485 | | 9 | 26,494 | |
| Net income / (loss) recognized in the income statement | - | 143 | | - | | - | | - | | - | | 143 | | - | 143 | |
| Other comprehensive income: | | | | | | | | | | | | | | | | |
| Items that will not be reclassified to profit or
loss: | | | | | | | | | | | | | | | | |
| Changes in revaluation reserve real estate held for own use | - | - | | (2 | ) | - | | - | | - | | (2 | ) | - | (2 | ) |
| Remeasurements of defined benefit plans | - | - | | - | | (501 | ) | - | | - | | (501 | ) | - | (501 | ) |
| Income tax relating to items that will not be reclassified | - | - | | - | | 136 | | - | | - | | 135 | | - | 135 | |
| Items that may be reclassified subsequently to profit or
loss: | | | | | | | | | | | | | | | | |
| Gains / (losses) on revaluation of available-for-sale investments | - | - | | 1,841 | | - | | - | | - | | 1,841 | | - | 1,841 | |
| (Gains) / losses transferred to income statement on disposal and impairment of
available-for-sale investments | - | - | | (30 | ) | - | | - | | - | | (30 | ) | - | (30 | ) |
| Changes in cash flow hedging reserve | - | - | | 304 | | - | | - | | - | | 304 | | - | 304 | |
| Movement in foreign currency translation and net foreign investment hedging
reserves | - | - | | - | | 53 | | (787 | ) | - | | (734 | ) | - | (734 | ) |
| Equity movements of joint ventures | - | - | | - | | - | | 3 | | - | | 3 | | - | 3 | |
| Equity movements of associates | - | - | | - | | - | | 1 | | - | | 1 | | - | 1 | |
| Income tax relating to items that may be reclassified | - | - | | (776 | ) | - | | 14 | | - | | (762 | ) | - | (762 | ) |
| Other | - | (1 | ) | - | | - | | - | | - | | (1 | ) | 7 | 6 | |
| Total other comprehensive
income | - | (1 | ) | 1,337 | | (313 | ) | (769 | ) | - | | 255 | | 7 | 261 | |
| Total comprehensive income / (loss) for 2016 | - | 143 | | 1,337 | | (313 | ) | (769 | ) | - | | 398 | | 7 | 405 | |
| Issuance and purchase of (treasury) shares | - | (200 | ) | - | | - | | - | | - | | (200 | ) | - | (200 | ) |
| Coupons on non-cumulative subordinated notes | - | (7 | ) | - | | - | | - | | - | | (7 | ) | - | (7 | ) |
| Coupons on perpetual securities | - | (28 | ) | - | | - | | - | | - | | (28 | ) | - | (28 | ) |
| Incentive plans | - | - | | - | | - | | - | | 11 | | 11 | | - | 11 | |
| At end of period | 8,387 | 7,984 | | 7,808 | | (1,845 | ) | 513 | | 3,811 | | 26,659 | | 16 | 26,674 | |
| Three months ended March 31, 2015 | | | | | | | | | | | | | | | | |
| At beginning of year (as previously stated) | 8,597 | 9,076 | | 8,308 | | (1,611 | ) | (77 | ) | 3,827 | | 28,120 | | 9 | 28,129 | |
| Changes in accounting policies relating to deferred cost of
reinsurance | - | (101 | ) | - | | - | | (9 | ) | - | | (110 | ) | - | (110 | ) |
| At beginning of year (restated) | 8,597 | 8,975 | | 8,308 | | (1,611 | ) | (86 | ) | 3,827 | | 28,010 | | 9 | 28,019 | |
| Net income / (loss) recognized in the income statement | - | 289 | | - | | - | | - | | - | | 289 | | - | 289 | |
| Other comprehensive income: | | | | | | | | | | | | | | | | |
| Items that will not be reclassified to profit or loss: | | | | | | | | | | | | | | | | |
| Changes in revaluation reserve real estate held for own use | - | - | | 5 | | - | | - | | - | | 5 | | - | 5 | |
| Remeasurements of defined benefit plans | - | - | | - | | (627 | ) | - | | - | | (627 | ) | - | (627 | ) |
| Income tax relating to items that will not be reclassified | - | - | | - | | 159 | | - | | - | | 159 | | - | 159 | |
| Items that may be reclassified subsequently to profit or
loss: | | | | | | | | | | | | | | | | |
| Gains / (losses) on revaluation of available-for-sale investments | - | - | | 1,595 | | - | | - | | - | | 1,595 | | - | 1,595 | |
| (Gains) / losses transferred to income statement on disposal and impairment of
available-for-sale investments | - | - | | (132 | ) | - | | - | | - | | (132 | ) | - | (132 | ) |
| Changes in cash flow hedging reserve | - | - | | 558 | | - | | - | | - | | 558 | | - | 558 | |
| Movement in foreign currency translation and net foreign investment hedging
reserves | - | - | | - | | (104 | ) | 1,823 | | - | | 1,718 | | - | 1,718 | |
| Equity movements of joint ventures | - | - | | - | | - | | 3 | | - | | 3 | | - | 3 | |
| Income tax relating to items that may be reclassified | - | - | | (400 | ) | - | | (50 | ) | - | | (450 | ) | - | (450 | ) |
| Other | - | 3 | | - | | - | | - | | - | | 3 | | - | 3 | |
| Total other comprehensive
income | - | 3 | | 1,625 | | (573 | ) | 1,776 | | - | | 2,830 | | - | 2,831 | |
| Total comprehensive income / (loss) for 2015 | - | 292 | | 1,625 | | (573 | ) | 1,776 | | - | | 3,119 | | - | 3,120 | |
| Issuance and purchase of (treasury) shares | - | 1 | | - | | - | | - | | - | | 1 | | - | 1 | |
| Coupons on non-cumulative subordinated notes | - | (7 | ) | - | | - | | - | | - | | (7 | ) | - | (7 | ) |
| Coupons on perpetual securities | - | (30 | ) | - | | - | | - | | - | | (30 | ) | - | (30 | ) |
| Share options and incentive plans | - | 10 | | - | | - | | - | | (2 | ) | 8 | | - | 8 | |
| At end of period | 8,597 | 9,242 | | 9,933 | | (2,184 | ) | 1,690 | | 3,825 | | 31,102 | | 9 | 31,111 | |

1 For a breakdown of share capital please refer to note 15.

2 Issued capital and reserves attributable to equity holders of Aegon N.V.

Amounts for 2015 have been restated for the voluntary changes in accounting policies for deferred cost of reinsurance and insurance accounting in the UK. Refer to note 2.1 Voluntary changes in accounting policies for details about these changes.

Unaudited

Table of Contents

6 Condensed Consolidated Interim Financial Statements Q1 2016

Condensed consolidated cash flow statement — EUR millions Q1 2016 Q1 2015
Cash flow from operating activities 2,799 2,338
Purchases and disposals of intangible assets (8 ) (2 )
Purchases and disposals of equipment and other assets (8 ) (15 )
Purchases, disposals and dividends of
subsidiaries, associates and joint ventures 23 330
Cash flow from investing activities 6 313
Issuance and purchase of (treasury) shares (200 ) -
Issuances, repurchases and coupons of perpetuals (37 ) (39 )
Issuances, repurchases and coupons of non-cumulative subordinated
notes (9 ) (9 )
Issuances and repayments of
borrowings (1,431 ) (210 )
Cash flow from financing activities (1,677 ) (258 )
Net increase / (decrease) in cash and cash
equivalents 1,128 2,393
Net cash and cash equivalents at January 1 9,593 10,649
Effects of changes in foreign exchange
rates (146 ) 235
Net cash and cash equivalents at end of
period 10,576 13,277
Cash and cash equivalents 10,616 13,236
Cash and cash equivalents classified as Assets held for sale - 46
Bank overdrafts classified as other
liabilities (40 ) (4 )
Net cash and cash
equivalents 10,576 13,277

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 7

Notes to the condensed consolidated interim financial statements

Amounts in EUR millions, unless otherwise stated

Aegon N.V., incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch law and recorded in the Commercial Register of The Hague under number 27076669 and with its registered address at Aegonplein 50, 2591 TV, The Hague, the Netherlands. Aegon N.V. serves as the holding company for the Aegon Group and has listings of its common shares in Amsterdam and New York.

Aegon N.V. (or ‘the Company’) and its consolidated subsidiaries (‘Aegon’ or ‘the Group’) have life insurance and pensions operations in over twenty five countries in the Americas, Europe and Asia and are also active in savings and asset management operations, accident and health insurance, general insurance and to a limited extent banking operations. Its headquarters are located in The Hague, the Netherlands. The Group employs close to 30,000 people worldwide.

1. Basis of presentation

The condensed consolidated interim financial statements as at, and for the period ended, March 31, 2016, have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’, as adopted by the European Union (hereafter ‘IFRS’). They do not include all of the information required for a full set of financial statements prepared in accordance with IFRS and should therefore be read together with the 2015 consolidated financial statements of Aegon N.V. as included in Aegon’s Annual Report for 2015 and the disclosures provided in note 2.1 of this report which disclose the impact of voluntary changes in accounting policies that were made by Aegon effective January 1, 2016. Aegon’s Annual Report for 2015 is available on its website (aegon.com).

The condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention as modified by the revaluation of investment properties and those financial instruments (including derivatives) and financial liabilities that have been measured at fair value.

The condensed consolidated interim financial statements as at, and for the period ended, March 31, 2016, were approved by the Executive Board on May 11, 2016.

The condensed consolidated interim financial statements are presented in euro (EUR) and all values are rounded to the nearest million unless otherwise stated. The consequence is that the rounded amounts may not add up to the rounded total in all cases.

The published figures in these condensed consolidated interim financial statements are unaudited.

2. Significant accounting policies

All accounting policies and methods of computation applied in the condensed consolidated interim financial statements are the same as those applied in the 2015 consolidated financial statements, except for the newly applied accounting policies as described in note 2.1.

Unaudited

Table of Contents

8 Condensed Consolidated Interim Financial Statements Q1 2016

New IFRS accounting standards effective

The following standards, interpretations, amendments to standards and interpretations became effective in 2016:

t IFRS 10, IFRS 12 and IAS 28 - Investment Entities: Applying the Consolidation Exception;

t IFRS 11 Joint Arrangements - Amendment Accounting for Acquisition of Interests in Joint Operations;

t IFRS 14 Regulatory Deferral Accounts;

t IAS 1 - Amendment Disclosure Initiative;

t IAS 27 Separate Financial Statements - Amendment Equity method in Separate Financial Statements;

t IAS 16 and IAS 38 Clarification of Acceptable Methods of Depreciation and Amortization; and

t Annual improvements 2012-2014 Cycle.

None of these revised standards and interpretations had a significant effect on the condensed consolidated interim financial statements as at and for the period ended March 31, 2016.

For a complete overview of IFRS standards, published before January 1, 2016, that will be applied in future years, and were not early adopted by the Group, please refer to Aegon’s Annual Report for 2015.

Taxes

Taxes on income for the three month period, ended March 31, 2016, are calculated using the tax rate that would be applicable to total annual earnings.

Judgments and critical accounting estimates

Preparing the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions, including the likelihood, timing or amount of future transactions or events, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from the estimates made.

In preparing the condensed consolidated interim financial statements, significant judgments made by management in applying the Group’s accounting policies and the key sources of estimating uncertainty were not significantly different than those that were applied to the consolidated financial statements as at and for the year ended December 31, 2015.

Exchange rates

Assets and liabilities are translated at the closing rates on the balance sheet date. Income, expenses and capital transactions (such as dividends) are translated at average exchange rates or at the prevailing rates on the transaction date, if more appropriate. The following exchange rates are applied for the condensed consolidated interim financial statements:

Closing exchange rates

March 31, 2016 1 EUR USD — 1.1396 GBP — 0.7928
December 31, 2015 1 EUR 1.0863 0.7370

Weighted average exchange rates

Three months ended March 31, 2016 1 EUR USD — 1.1023 GBP — 0.7698
Three months ended March 31, 2015 1 EUR 1.1272 0.7434

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 9

2.1 Voluntary changes in accounting policies

On January 13, 2016, Aegon provided an update on its strategic plans at its Analyst & Investor Conference. Following this update Aegon adopted voluntary changes in accounting policies, effective January 1, 2016, which are applied retrospectively for all periods presented. Firstly, Aegon adopted a group-wide accounting policy for reinsurance transactions that are entered into as part of a plan to exit a business. Also, Aegon made two voluntary accounting policy changes that better reflect its business strategy after restructuring in the United Kingdom. The changes in the United Kingdom do not impact other reporting units within Aegon as these are changes specific to Aegon UK. However, these changes do increase alignment with other reporting units within Aegon. Finally Aegon changed its segment reporting.

In the paragraphs below, details are provided for the changes in accounting policies including the impact on shareholders equity and net income. The changes in segment reporting are explained in note 3.

Accounting related to certain reinsurance transactions

Aegon adopted one single group-wide accounting policy for reinsurance transactions that are entered into as part of a plan to exit a business. The previous accounting policy recorded a deferred cost of reinsurance which was subsequently amortized. Under the new accounting policy, when the company enters into a reinsurance contract as part of a plan to exit a business, an immediate gain or loss will be recognized in the income statement.

For purposes of this accounting policy, a business is defined as “designated insurance liabilities to be disposed of through reinsurance transactions”. The insurance liabilities are designated according to their homogenous risk profiles, possible examples include but are not limited to geographical area, product type, distribution channel, policyholder profiles, and policy form or riders.

Insurance accounting for business in United Kingdom

In January 2016, Aegon announced the restructuring of its business and operations in the UK. This involves splitting the Aegon UK business into three components: the annuity business, the traditional pension book and the new digital solutions platform. By extracting the digital solutions platform from the rest of the business, management aims to ensure the focus and separate culture required to successfully build a viable and sustainably growing business over the longer term.

Aegon adopts two voluntary accounting policy changes that better reflect its business strategy after restructuring in the United Kingdom, only affecting Aegon UK. The changes involve the aggregation level at which the liability adequacy test is carried out and the definition of when a substantially modified contract will be derecognized.

Level of aggregation

The previous accounting policy for the level of aggregation for the liability adequacy test in the United Kingdom was on a geographical basis, therefore the total Aegon UK book is considered as one population. After the announced restructuring, Aegon’s business in the United Kingdom has been split into different portfolios that are managed independently from one another. Management is of the opinion that the liability adequacy test should be disaggregated to a portfolio level to reflect this change in strategy. This change in the definition of portfolio for Aegon UK will better align with other reporting units in the Group where insurance contracts are grouped consistent with the Company’s manner of acquiring, servicing and measuring the profitability of its insurance contracts.

Unaudited

Table of Contents

10 Condensed Consolidated Interim Financial Statements Q1 2016

Substantial modification

The previous accounting policy for Aegon’s business in the United Kingdom is to derecognize insurance contracts when legal extinguishment occurs. As the annuity business, the traditional pension book and the new digital solutions platform will be managed separately post-restructuring, Aegon has decided to change its accounting policy for Aegon UK to one that applies criteria from IAS 39 contract modification. Under these criteria a change should be significant enough to be considered an extinguishment of the existing contract and the issuance of a new contract. Aegon considers that this change in accounting policy is preferred as introducing a more sophisticated approach to contract modification is consistent with how the business will be managed post-restructuring. Furthermore, it will provide the user with information that is more relevant and that reliably reflects the economic substance of our transactions with our upgraded policyholders, as required by IFRS 4 and IAS 8, in relation to the nature of contract modifications.

Details of the impact of the adjustments on previous periods are provided in the following tables:

| Impact of voluntary changes in accounting policies on condensed consolidated income
statement | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | | Change in accounting policy | | | | | |
| | Notes | Q1 2015 | 1) | Deferred cost of reinsurance | | Insurance accounting in UK | | Q1 2015 (restated) | |
| EUR millions | | | | | | | | | |
| Premium income | 4 | 5,641 | | - | | 706 | | 6,347 | |
| Benefits and expenses | 7 | 18,392 | | (8 | ) | 743 | | 19,127 | |
| Income tax (expense) / benefit | | (101 | ) | (6 | ) | 7 | | (100 | ) |
| Impact on net income | | | | 2 | | (29 | ) | | |
| Earnings per share (EUR per share) | 15 | | | | | | | | |
| Basic earnings per common share | | 0.13 | | - | | (0.01 | ) | 0.12 | |
| Basic earnings per common share B | | - | | - | | - | | - | |
| Diluted earnings per common share | | 0.13 | | - | | (0.01 | ) | 0.12 | |
| Diluted earnings per common share
B | | - | | - | | - | | - | |
| Earnings per share calculation | 15 | | | | | | | | |
| Net income / (loss) attributable to equity holders of Aegon N.V. | | 316 | | 2 | | (29 | ) | 289 | |
| Coupons on other equity
instruments | | (36 | ) | - | | - | | (36 | ) |
| Earnings attributable to common shares and common shares B | | 280 | | 2 | | (29 | ) | 253 | |
| Weighted average number of common shares outstanding (in million) | | 2,095 | | - | | - | | 2,095 | |
| Weighted average number of common shares B
outstanding (in million) | | 581 | | - | | - | | 581 | |

1 Note that premium income and expenses have been updated for the adjustments made in Q2 2015.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 11

| Impact
of voluntary changes in accounting policies on condensed consolidated income statement | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | | Change in accounting policy | | | | | |
| | Notes | FY 2015 (as previously reported) 1) | | Deferred cost of reinsurance | | Insurance accounting in UK | | FY 2015 (restated) | |
| EUR millions | | | | | | | | | |
| Premium income | 4 | 20,311 | | - | | 2,614 | | 22,925 | |
| Benefits and expenses | 7 | 33,325 | | (36 | ) | 2,763 | | 36,052 | |
| Impairment charges / (reversals) | 8 | (22 | ) | - | | 1,274 | | 1,251 | |
| Income tax (expense) / benefit | | (134 | ) | (26 | ) | 270 | | 111 | |
| Impact on net income | | | | 10 | | (1,153 | ) | | |
| Earnings per share (EUR per share) | 15 | | | | | | | | |
| Basic earnings per common share | | 0.23 | | - | | (0.54 | ) | (0.31 | ) |
| Basic earnings per common share B | | 0.01 | | - | | (0.01 | ) | (0.01 | ) |
| Diluted earnings per common share | | 0.23 | | - | | (0.54 | ) | (0.31 | ) |
| Diluted earnings per common share
B | | 0.01 | | - | | (0.01 | ) | (0.01 | ) |
| Earnings per share calculation | 15 | | | | | | | | |
| Net income / (loss) attributable to equity holders of Aegon N.V. | | 619 | | 10 | | (1,153 | ) | (524 | ) |
| Coupons on other equity
instruments | | (139 | ) | - | | - | | (139 | ) |
| Earnings attributable to common shares and common shares B | | 479 | | 10 | | (1,153 | ) | (663 | ) |
| Weighted average number of common shares outstanding (in million) | | 2,101 | | - | | - | | 2,101 | |
| Weighted average number of common shares B
outstanding (in million) | | 584 | | - | | - | | 584 | |

1 As reported in Aegon’s 2015 Annual Report dated March 25, 2016.

| Impact of voluntary changes in accounting policies on condensed consolidated statement
of comprehensive income | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | Change in accounting policy | | | | |
| | Q1 2015 (as previously reported) | Deferred cost of reinsurance | | Insurance accounting in UK | | Q1 2015 (restated) |
| EUR millions | | | | | | |
| Net income | 316 | 2 | | (29 | ) | 289 |
| Items that may be reclassified subsequently to profit or
loss: | | | | | | |
| Movement in foreign currency translation and net foreign investment hedging
reserves | 1,733 | (14 | ) | (1 | ) | 1,718 |
| Impact on comprehensive
income | | (11 | ) | (30 | ) | |
| Total comprehensive income / (loss) attributable to: | | | | | | |
| Equity holders of Aegon N.V. | 3,161 | (11 | ) | (30 | ) | 3,119 |
| Non-controlling interests | - | - | | - | | - |

| Impact of voluntary changes in accounting policies on condensed consolidated statement
of comprehensive income | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | | Change in accounting policy | | | | | |
| | FY 2015 (as previously reported) 1) | Deferred cost of reinsurance | | Insurance accounting in UK | | FY 2015 (restated) | |
| EUR millions | | | | | | | |
| Net income | 619 | 10 | | (1,153 | ) | (523 | ) |
| Items that may be reclassified subsequently to profit or
loss: | | | | | | | |
| Movement in foreign currency translation and net foreign investment hedging
reserves | 1,414 | (12 | ) | 18 | | 1,419 | |
| Impact on comprehensive
income | | (2 | ) | (1,135 | ) | | |
| Total comprehensive income / (loss) attributable to: | | | | | | | |
| Equity holders of Aegon N.V. | 234 | (2 | ) | (1,135 | ) | (903 | ) |
| Non-controlling interests | - | - | | - | | - | |

1 As reported in Aegon’s 2015 Annual Report dated March 25, 2016.

Unaudited

Table of Contents

12 Condensed Consolidated Interim Financial Statements Q1 2016

| Impact of changes in accounting policies on the condensed consolidated statement of
financial position | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | | | Change in accounting policy | | | | |
| | Notes | December 31, 2015
(as previously reported) 1) | Deferred cost of reinsurance | | Insurance accounting in UK | | December 31, 2015 (restated) |
| EUR millions | | | | | | | |
| Assets | | | | | | | |
| Intangible assets | 9 | 2,110 | - | | (210 | ) | 1,901 |
| Deferred expenses | 14 | 12,547 | (358 | ) | (1,192 | ) | 10,997 |
| Equity and liabilities | | | | | | | |
| Shareholders’ equity | | 23,931 | (112 | ) | (1,135 | ) | 22,684 |
| Insurance contracts | | 123,042 | - | | - | | 123,042 |
| Investment contracts | | 17,718 | - | | - | | 17,718 |
| Other liabilities | | 21,940 | (247 | ) | (266 | ) | 21,427 |

1 As reported in Aegon’s 2015 Annual Report dated March 25, 2016.

| Impact of voluntary changes in accounting policies on condensed consolidated statement
of changes in equity | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | Change in accounting policy | | | | | |
| | December 31, 2015
(as previously reported) 1) | | Deferred cost of reinsurance | | Insurance accounting in UK | | December 31, 2015 (restated) | |
| EUR millions | | | | | | | | |
| Share capital | 8,387 | | - | | - | | 8,387 | |
| Retained earnings | 9,319 | | (91 | ) | (1,153 | ) | 8,075 | |
| Revaluation reserves | 6,471 | | - | | - | | 6,471 | |
| Remeasurement of defined benefit plans | (1,532 | ) | - | | - | | (1,532 | ) |
| Other reserves | 1,286 | | (21 | ) | 18 | | 1,283 | |
| Shareholders’ equity | 23,931 | | (112 | ) | (1,135 | ) | 22,684 | |

1 As reported in Aegon’s 2015 Annual Report dated March 25, 2016.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 13

3. Segment information

Based on the amended strategic plans as announced on January 13, 2016, Aegon has reconsidered its segment reporting. Aegon’s current segment reporting was established in 2010 considering the requirements outlined in IFRS 8 – Operating Segments. IFRS 8 requires operating segments to be defined in line with how the ‘chief operating decision maker’ (CODM, i.e. Aegon’s Executive Board) manages the business. Currently, Aegon has the following reportable segments: Americas, The Netherlands, United Kingdom, New Markets and Holdings and other activities. New Markets was established to aggregate Aegon’s emerging businesses and global / European initiatives which is a combination of the following operating segments: Central & Eastern Europe, Asia, Spain & Portugal, Asset Management and Variable Annuities Europe (VA Europe). Under IFRS 8 these operating segments were aggregated as one reportable segment due to their respective size.

Given that Aegon changed its managerial view to geographical areas and underlying businesses have developed since 2010, internal management reports have been changed as of 2016 accordingly. Alignment of segment reporting with those changes and developments have been put in place in 2016 reflecting Aegon’s announcements related to its strategic plan. This means that the operating segments as described above have been presented on this basis and introduces separate presentation of the asset management business. The following will be reported from 2016 onwards:

t Americas: one operating segment which covers business units in the United States, Brazil and Mexico, including any of the units’ activities located outside these countries;

t Europe: which covers the following operating segments: the Netherlands, United Kingdom (including VA Europe), Central & Eastern Europe, Spain and Portugal;

t Asia: one operating segment which covers businesses operating in Hong Kong, China, Japan, India and Indonesia including any of the units’ activities located outside these countries;

t Asset Management: one operating segment which covers business activities from Aegon Asset Management;

t Holding and other activities: one operating segment which includes financing, employee and other administrative expenses of holding companies.

For Europe, the underlying businesses (the Netherlands, United Kingdom including VA Europe, Central & Eastern Europe and Spain and Portugal) are separate operating segments which under IFRS 8 cannot be aggregated, therefore further details will be provided for these operating segments.

The change in segment reporting does not have an impact on the financial position, results of operations or cash flows of Aegon.

Unaudited

Table of Contents

14 Condensed Consolidated Interim Financial Statements Q1 2016

The following table shows the segments as previously reported excluding voluntary changes in accounting policies (as presented in note 2.1):

EUR millions
Three months ended March 31,
2015
Underlying earnings before tax
geographically 290 131 38 51 (40 ) (2 ) 469 3 472
Fair value items (90 ) 151 (22 ) (4 ) (193 ) - (159 ) (8 ) (167 )
Realized gains / (losses) on
investments (29 ) 140 2 5 - - 119 (2 ) 116
Impairment charges (7 ) (7 ) - (2 ) - - (16 ) - (16 )
Impairment reversals 3 2 - - - - 5 - 5
Other income / (charges) - (22 ) 21 - - - (1 ) - (1 )
Run-off
businesses 8 - - - - - 8 - 8
Income/ (loss) before tax 175 396 39 50 (233 ) (2 ) 425 (8 ) 418
Income tax
(expense) / benefit (30 ) (92 ) (21 ) (22 ) 57 - (109 ) 8 (101 )
Net income/
(loss) 145 304 18 28 (176 ) (2 ) 316 - 316
Inter-segment underlying
earnings (53 ) (13 ) (16 ) 80 3
Revenues
Life insurance gross premiums 1,693 1,046 1,371 757 - (24 ) 4,842 (119 ) 4,723
Accident and health insurance 552 129 13 60 1 (1 ) 754 (11 ) 743
General
insurance - 131 - 63 - - 194 (19 ) 175
Total gross premiums 2,244 1,306 1,383 879 1 (26 ) 5,789 (149 ) 5,641
Investment income 908 590 544 117 94 (95 ) 2,158 (61 ) 2,098
Fee and commission income 406 85 12 196 - (68 ) 630 (48 ) 582
Other
revenues 1 - - 1 1 - 3 (1 ) 2
Total
revenues 3,559 1,981 1,939 1,193 97 (188 ) 8,580 (258 ) 8,322
Inter-segment
revenues 6 - - 86 96

The following table shows the new segments excluding voluntary changes in accounting policies:

EUR millions
Three months ended March 31,
2015
Underlying earnings before
tax 290 131 39 5 3 178 (3 ) 45 (40 ) (2 ) 469 3 472
Fair value items (90 ) 151 (33 ) - - 118 6 - (193 ) - (159 ) (8 ) (167 )
Realized gains / (losses) on
investments (29 ) 140 2 - - 142 4 1 - - 119 (2 ) 116
Impairment charges (7 ) (7 ) - (2 ) - (9 ) - - - - (16 ) - (16 )
Impairment reversals 3 2 - - - 2 - - - - 5 - 5
Other income / (charges) - (22 ) 21 - - (1 ) - - - - (1 ) - (1 )
Run-off
businesses 8 - - - - - - - - - 8 - 8
Income / (loss) before tax 175 396 29 4 3 431 7 46 (233 ) (2 ) 425 (8 ) 418
Income tax
(expense) / benefit (30 ) (92 ) (20 ) (4 ) (2 ) (118 ) (4 ) (14 ) 57 - (109 ) 8 (101 )
Net income /
(loss) 145 304 9 - 1 313 4 32 (176 ) (2 ) 316 - 316
Inter-segment underlying
earnings (53 ) (13 ) (15 ) (4 ) - (32 ) 18 65 3
Revenues
Life insurance gross premiums 1,693 1,046 1,420 146 49 2,661 512 - - (24 ) 4,842 (119 ) 4,723
Accident and health insurance 552 129 13 - 25 168 34 - 1 (1 ) 754 (11 ) 743
General
insurance - 131 - 44 19 194 - - - - 194 (19 ) 175
Total gross premiums 2,244 1,306 1,433 190 94 3,023 546 - 1 (26 ) 5,789 (149 ) 5,641
Investment income 908 590 545 12 11 1,158 92 1 96 (96 ) 2,158 (61 ) 2,098
Fee and commission income 406 85 25 11 3 124 20 149 - (70 ) 630 (48 ) 582
Other
revenues 1 - - - 1 1 - - 1 - 3 (1 ) 2
Total
revenues 3,559 1,981 2,003 213 108 4,305 658 151 98 (191 ) 8,580 (258 ) 8,322
Inter-segment
revenues 6 - - - - - 24 64 97

The following table shows the impact of the voluntary changes in accounting policies (as presented in note 2.1) on the new segments:

EUR millions
Three months ended March 31,
2015
Underlying earnings before
tax - - (37 ) - - (37 ) - - - - (37 ) - (37 )
Fair value items - - - - - - - - - - - - -
Realized gains / (losses) on
investments - - - - - - - - - - - - -
Impairment charges - - - - - - - - - - - - -
Impairment reversals - - - - - - - - - - - - -
Other income / (charges) - - - - - - - - - - - - -
Run-off
businesses 8 - - - - - - - - - 8 - 8
Income / (loss) before tax 8 - (37 ) - - (37 ) - - - - (29 ) - (29 )
Income tax
(expense) / benefit (6 ) - 7 - - 7 - - - - 2 - 2
Net income /
(loss) 2 - (29 ) - - (29 ) - - - - (27 ) - (27 )
Inter-segment underlying
earnings - - - - - - - - -
Revenues
Life insurance gross premiums - - 706 - - 706 - - - - 706 - 706
Accident and health insurance - - - - - - - - - - - - -
General
insurance - - - - - - - - - - - - -
Total gross premiums - - 706 - - 706 - - - - 706 - 706
Investment income - - - - - - - - - - - - -
Fee and commission income - - - - - - - - - - - - -
Other
revenues - - - - - - - - - - - - -
Total
revenues - - 706 - - 706 - - - - 706 - 706
Inter-segment
revenues - - - - - - - - -

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 15

The following table shows the new segment figures taken into account the voluntary changes in accounting policies (as presented in note 2.1):

EUR millions
Three months ended March 31,
2015
Underlying earnings before
tax 290 131 2 5 3 141 (3 ) 45 (40 ) (2 ) 432 3 435
Fair value items (90 ) 151 (33 ) - - 118 6 - (193 ) - (159 ) (8 ) (167 )
Realized gains / (losses) on
investments (29 ) 140 2 - - 142 4 1 - - 119 (2 ) 116
Impairment charges (7 ) (7 ) - (2 ) - (9 ) - - - - (16 ) - (16 )
Impairment reversals 3 2 - - - 2 - - - - 5 - 5
Other income / (charges) - (22 ) 21 - - (1 ) - - - - (1 ) - (1 )
Run-off
businesses 16 - - - - - - - - - 16 - 16
Income / (loss) before tax 183 396 (8 ) 4 3 394 7 46 (233 ) (2 ) 396 (8 ) 389
Income tax
(expense) / benefit (36 ) (92 ) (12 ) (4 ) (2 ) (110 ) (4 ) (14 ) 57 - (107 ) 8 (100 )
Net income /
(loss) 147 304 (20 ) - 1 284 4 32 (176 ) (2 ) 289 - 289
Inter-segment underlying
earnings (53 ) (13 ) (15 ) (4 ) - (32 ) 18 65 3
Revenues
Life insurance gross premiums 1,693 1,046 2,126 146 49 3,367 512 - - (24 ) 5,547 (119 ) 5,429
Accident and health insurance 552 129 13 - 25 168 34 - 1 (1 ) 754 (11 ) 743
General
insurance - 131 - 44 19 194 - - - - 194 (19 ) 175
Total gross premiums 2,244 1,306 2,139 190 94 3,729 546 - 1 (26 ) 6,495 (149 ) 6,347
Investment income 908 590 545 12 11 1,158 92 1 96 (96 ) 2,158 (61 ) 2,098
Fee and commission income 406 85 25 11 3 124 20 149 - (70 ) 630 (48 ) 582
Other
revenues 1 - - - 1 1 - - 1 - 3 (1 ) 2
Total
revenues 3,559 1,981 2,709 213 108 5,011 658 151 98 (191 ) 9,286 (258 ) 9,028
Inter-segment
revenues 6 - - - - - 24 64 97

Aegon’s segment information is prepared by consolidating on a proportionate basis Aegon’s joint ventures and associated companies.

Performance Measure

A performance measure of reporting segments utilized by the Company is underlying earnings before tax. Underlying earnings before tax reflects Aegon’s profit from underlying business operations and excludes components that relate to accounting mismatches that are dependent on market volatility or relate to events that are considered outside the normal course of business.

Aegon believes that its performance measure, underlying earnings before tax, provides meaningful information about the underlying results of Aegon’s business, including insight into the financial measures that Aegon’s senior management uses in managing the business. Among other things, Aegon’s senior management is compensated based in part on Aegon’s results against targets using underlying earnings before tax. While many other insurers in Aegon’s peer group present substantially similar performance measures, the performance measures presented in this document may nevertheless differ from the performance measures presented by other insurers. There is no standardized meaning to these measures under IFRS or any other recognized set of accounting standards.

The reconciliation from underlying earnings before tax to income before tax, being the most comparable IFRS measure, is presented in the tables in this note.

The items that are excluded from underlying earnings before tax as described further below are: fair value items, realized gain or losses on investments, impairment charges/reversals, other income or charges, run-off businesses and share in earnings of joint ventures and associates.

Fair value items

Fair value items include the over- or underperformance of investments and guarantees held at fair value for which the expected long-term return is included in underlying earnings before tax. Changes to these long-term return assumptions are also included in the fair value items.

Unaudited

Table of Contents

16 Condensed Consolidated Interim Financial Statements Q1 2016

In addition, hedge ineffectiveness on hedge transactions, fair value changes on economic hedges without natural offset in earnings and for which no hedge accounting is applied and fair value movements on real estate are included under fair value items.

Certain assets held by Aegon are carried at fair value and managed on a total return basis, with no offsetting changes in the valuation of related liabilities. These include assets such as investments in hedge funds, private equities, real estate (limited partnerships), convertible bonds and structured products. Underlying earnings before tax exclude any over- or underperformance compared to management’s long-term expected return on assets. Based on current holdings and asset returns, the long-term expected return on an annual basis is 8-10%, depending on asset class, including cash income and market value changes. The expected earnings from these asset classes are net of deferred policy acquisition costs (DPAC) where applicable.

In addition, certain products offered by Aegon Americas contain guarantees and are reported on a fair value basis and the total return annuities and guarantees on variable annuities. The earnings on these products are impacted by movements in equity markets and risk-free interest rates. Short-term developments in the financial markets may therefore cause volatility in earnings. Included in underlying earnings before tax is a long-term expected return on these products and excluded is any over- or underperformance compared to management’s expected return.

The fair value movements of certain guarantees and the fair value change of derivatives that hedge certain risks on these guarantees of Aegon the Netherlands and VA Europe (included in United Kingdom) are excluded from underlying earnings before tax, and the long-term expected return for these guarantees is set at zero. In addition fair value items include market related results on our loyalty bonus reserves in the United Kingdom. The value of these reserves are directly related to policyholder investments which value is directly impacted by movements in equity and bond markets.

Holding and other activities include certain issued bonds that are held at fair value through profit or loss (FVTPL). The interest rate risk on these bonds is hedged using swaps. The fair value movement resulting from changes in Aegon’s credit spread used in the valuation of these bonds are excluded from underlying earnings before tax and reported under fair value items.

Realized gains or losses on investments

Includes realized gains and losses on available-for-sale investments, mortgage loans and other loan portfolios.

Impairment charges/reversals

Impairment charges include impairments on available-for-sale debt securities, shares including the effect of deferred policyholder acquisition costs, mortgage loans and other loan portfolios at amortized cost, joint ventures and associates. Impairment reversals include reversals on available-for-sale debt securities.

Other income or charges

Other income or charges is used to report any items which cannot be directly allocated to a specific line of business. Also items that are outside the normal course of business are reported under this heading. The impact of model updates used to support calculations of our liabilities for insurance and investment contracts sold to policyholders and related assets are reported under this caption as well.

Other charges may include restructuring charges that are considered other charges for segment reporting purposes because they are outside the normal course of business. In the condensed consolidated interim financial statements, these charges are included in operating expenses.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 17

Run-off businesses

Includes underlying results of business units where management has decided to exit the market and to run-off the existing block of business. Currently, this line includes results related to the run-off of the institutional spread-based business, structured settlements blocks of business, bank-owned and corporate-owned life insurance (BOLI/COLI) business, and the sale of the life reinsurance business in the United States. Aegon has other blocks of business for which sales have been discontinued and of which the earnings are included in underlying earnings before tax.

Share in earnings of joint ventures and associates

Earnings from Aegon’s joint ventures in the Netherlands, Mexico, Spain, Portugal, China and Japan and Aegon’s associates in India, Brazil, the Netherlands, United Kingdom, Mexico and France are reported on an underlying earnings before tax basis.

Unaudited

Table of Contents

18 Condensed Consolidated Interim Financial Statements Q1 2016

3.1 Income statement

EUR millions
Three months ended March 31,
2016
Underlying earnings before
tax 283 128 23 15 3 169 - 45 (37 ) 1 462 6 468
Fair value items (220 ) (105 ) 34 - - (71 ) 3 - (70 ) - (358 ) (13 ) (370 )
Realized gains / (losses) on
investments 33 18 1 - (1 ) 17 4 - - - 54 (1 ) 53
Impairment charges (34 ) (5 ) - 2 - (3 ) (1 ) - (4 ) - (42 ) - (42 )
Impairment reversals 2 4 - - - 4 - - - - 6 - 6
Other income / (charges) (6 ) - 1 - - 1 - - - - (6 ) - (6 )
Run-off
businesses 28 - - - - - - - - - 28 - 28
Income / (loss) before tax 87 40 58 16 2 116 6 45 (110 ) 1 145 (7 ) 138
Income tax
(expense) / benefit 7 (7 ) (6 ) (2 ) (2 ) (17 ) (5 ) (13 ) 26 - (1 ) 7 6
Net income /
(loss) 94 33 52 14 - 99 1 32 (84 ) 1 143 - 143
Inter-segment underlying
earnings (55 ) (12 ) (13 ) (3 ) - (28 ) 21 65 (3 )
Revenues
Life insurance gross premiums 1,770 858 2,015 98 49 3,020 299 - 1 (21 ) 5,069 (170 ) 4,899
Accident and health insurance 548 121 11 - 72 204 33 - 4 (1 ) 787 (11 ) 775
General
insurance - 115 - 47 23 184 - - - - 184 (23 ) 161
Total gross premiums 2,318 1,094 2,026 145 144 3,408 331 - 5 (22 ) 6,040 (204 ) 5,836
Investment income 916 522 431 11 10 974 57 1 81 (81 ) 1,948 (13 ) 1,935
Fee and commission income 418 86 23 9 3 121 14 167 - (64 ) 656 (54 ) 602
Other
revenues 1 - - - 1 1 - - 1 - 2 (1 ) 1
Total
revenues 3,652 1,702 2,480 164 157 4,504 403 168 87 (167 ) 8,646 (272 ) 8,374
Inter-segment
revenues - 1 - - - 1 20 64 82
EUR millions
Three months ended March 31,
2015
Underlying earnings before
tax 290 131 2 5 3 141 (3 ) 45 (40 ) (2 ) 432 3 435
Fair value items (90 ) 151 (33 ) - - 118 6 - (193 ) - (159 ) (8 ) (167 )
Realized gains / (losses) on
investments (29 ) 140 2 - - 142 4 1 - - 119 (2 ) 116
Impairment charges (7 ) (7 ) - (2 ) - (9 ) - - - - (16 ) - (16 )
Impairment reversals 3 2 - - - 2 - - - - 5 - 5
Other income / (charges) - (22 ) 21 - - (1 ) - - - - (1 ) - (1 )
Run-off
businesses 16 - - - - - - - - - 16 - 16
Income / (loss) before tax 183 396 (8 ) 4 3 394 7 46 (233 ) (2 ) 396 (8 ) 389
Income tax
(expense) / benefit (36 ) (92 ) (12 ) (4 ) (2 ) (110 ) (4 ) (14 ) 57 - (107 ) 8 (100 )
Net income /
(loss) 147 304 (20 ) - 1 284 4 32 (176 ) (2 ) 289 - 289
Inter-segment underlying
earnings (53 ) (13 ) (15 ) (4 ) - (32 ) 18 65 3
Revenues
Life insurance gross premiums 1,693 1,046 2,126 146 49 3,367 512 - - (24 ) 5,547 (119 ) 5,429
Accident and health insurance 552 129 13 - 25 168 34 - 1 (1 ) 754 (11 ) 743
General
insurance - 131 - 44 19 194 - - - - 194 (19 ) 175
Total gross premiums 2,244 1,306 2,139 190 94 3,729 546 - 1 (26 ) 6,495 (149 ) 6,347
Investment income 908 590 545 12 11 1,158 92 1 96 (96 ) 2,158 (61 ) 2,098
Fee and commission income 406 85 25 11 3 124 20 149 - (70 ) 630 (48 ) 582
Other
revenues 1 - - - 1 1 - - 1 - 3 (1 ) 2
Total
revenues 3,559 1,981 2,709 213 108 5,011 658 151 98 (191 ) 9,286 (258 ) 9,028
Inter-segment
revenues 6 - - - - - 24 64 97

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 19

3.2 Investments

Amounts included in the tables on investments are presented on an IFRS basis.

March 31, 2016 Americas The Netherlands United Kingdom Central & Eastern Europe Spain & Portugal Europe Asia Asset Management Holdings and other activities Eliminations Total EUR
Investments
Shares 655 131 470 32 6 639 - 3 115 - 1,411
Debt securities 66,384 24,496 12,569 566 642 38,273 4,456 - - - 109,112
Loans 9,569 28,529 - 367 59 28,956 18 - - - 38,542
Other financial assets 11,273 355 138 10 - 503 - 51 18 - 11,845
Investments in real estate 715 1,158 - 2 - 1,160 - - - - 1,874
Investments general account 88,595 54,669 13,177 977 707 69,530 4,473 54 133 - 162,784
Shares - 8,888 15,479 276 12 24,653 - - - (7 ) 24,647
Debt securities 4,754 15,264 11,114 250 12 26,641 - - - - 31,395
Unconsolidated investment funds 91,844 17 35,361 919 56 36,353 - - - - 128,197
Other financial assets 13 3,135 3,127 16 - 6,278 - - - - 6,290
Investments in real estate - - 758 - - 758 - - - - 758
Investments for account of policyholders 96,611 27,303 65,837 1,461 81 94,682 - - - (7 ) 191,286
Investments on balance sheet 185,206 81,973 79,014 2,438 788 164,212 4,473 54 133 (7 ) 354,070
Off balance sheet investments third parties 213,627 874 3,990 2,967 512 8,342 2,357 209,822 - (83,665 ) 350,483
Total revenue generating investments 398,833 82,846 83,003 5,405 1,299 172,554 6,830 209,876 133 (83,672 ) 704,554
Investments
Available-for-sale 74,631 23,570 12,883 589 648 37,691 4,437 44 18 - 116,821
Loans 9,569 28,529 - 367 59 28,956 18 - - - 38,542
Financial assets at fair value through profit or loss 100,292 28,715 65,373 1,479 81 95,648 19 9 115 (7 ) 196,076
Investments in real estate 715 1,158 758 2 - 1,917 - - - - 2,632
Total investments on balance sheet 185,206 81,973 79,014 2,438 788 164,212 4,473 54 133 (7 ) 354,070
Investments in joint ventures 6 789 - - 515 1,305 132 114 1 - 1,558
Investments in associates 80 20 8 - - 28 16 128 - - 252
Other assets 26,601 22,348 5,958 299 294 28,885 2,735 290 33,698 (33,501 ) 58,722
Consolidated total assets 211,893 105,130 84,980 2,737 1,597 194,430 7,355 586 33,832 (33,508 ) 414,602
December 31, 2015 Americas The Netherlands United Kingdom Central & Eastern Europe Spain & Portugal Europe Asia Asset Management Holdings and other activities Eliminations Total EUR
Investments
Shares 652 136 506 38 2 682 - 2 124 - 1,460
Debt securities 65,284 23,370 13,185 525 636 37,715 4,391 - - - 107,390
Loans 10,062 28,007 - 340 62 28,409 19 - 88 - 38,577
Other financial assets 10,783 335 160 6 2 503 - 72 18 - 11,376
Investments in real estate 840 1,148 - 2 - 1,150 - - - - 1,990
Investments general account 87,620 52,996 13,850 911 702 68,459 4,409 74 230 - 160,792
Shares - 9,174 17,274 247 12 26,707 - - - (8 ) 26,699
Debt securities 4,967 14,642 11,728 256 13 26,640 - - - - 31,606
Unconsolidated investment funds 96,187 17 37,622 959 61 38,658 - - - - 134,845
Other financial assets 10 2,923 3,115 6 1 6,044 - - - - 6,054
Investments in real estate - - 1,022 - - 1,022 - - - - 1,022
Investments for account of policyholders 101,164 26,756 70,760 1,468 87 99,070 - - - (8 ) 200,226
Investments on balance sheet 188,784 79,752 84,610 2,379 789 167,529 4,409 74 230 (8 ) 361,019
Off balance sheet investments third parties 212,704 897 3,899 2,855 508 8,158 2,317 213,320 - (87,059 ) 349,440
Total revenue generating investments 401,487 80,648 88,509 5,234 1,297 175,687 6,727 213,394 230 (87,067 ) 710,458
Investments
Available-for-sale 72,761 22,479 13,534 545 638 37,195 4,370 65 18 - 114,409
Loans 10,062 28,007 - 340 62 28,409 19 - 88 - 38,577
Financial assets at fair value through profit or loss 105,121 28,119 70,054 1,493 88 99,753 21 9 124 (8 ) 205,020
Investments in real estate 840 1,148 1,022 2 - 2,171 - - - - 3,012
Total investments on balance sheet 188,784 79,752 84,610 2,379 789 167,529 4,409 74 230 (8 ) 361,019
Investments in joint ventures 7 837 - - 505 1,341 101 109 3 - 1,561
Investments in associates 75 19 9 - - 28 12 126 - - 242
Other assets 27,396 17,349 5,204 322 124 22,984 3,070 304 31,020 (31,881 ) 52,908
Consolidated total assets 216,262 97,956 89,822 2,701 1,417 191,882 7,592 613 31,254 (31,889 ) 415,729

Unaudited

Table of Contents

20 Condensed Consolidated Interim Financial Statements Q1 2016

4. Premium income

EUR millions Q1 2016 Q1 2015
Premium income
Life 4,899 5,429
Non-Life 937 918
Total 5,836 6,347
Premiums paid to reinsurers 1
Life 646 620
Non-Life 67 69
Total 713 689

1 Premiums paid to reinsurers are recorded within Benefits and expenses in the income statement - refer to note 7 - Benefits and expenses.

Premium income Life includes EUR 802 million (Q1 2015: EUR 849 million of premiums related to insurance policies upgraded to the new retirement platform in the UK.

5. Investment income

EUR millions Q1 2016 Q1 2015
Interest income 1,707 1,762
Dividend income 194 301
Rental income 34 35
Total investment income 1,935 2,098
Investment income related to general account 1,493 1,504
Investment income for account of
policyholders 442 594
Total 1,935 2,098

6. Results from financial transactions

| EUR millions — Net fair value change of general account financial investments at FVTPL other than
derivatives | Q1 2016 — (72 | ) | Q1 2015 — 71 | |
| --- | --- | --- | --- | --- |
| Realized gains /(losses) on financial investments | 53 | | 136 | |
| Gains /(losses) on investments in real estate | 18 | | 10 | |
| Net fair value change of derivatives | 438 | | 1,407 | |
| Net fair value change on for account of policyholder financial assets at
FVTPL | 1,596 | | 8,300 | |
| Net fair value change on investments in real estate for account of
policyholders | 8 | | 7 | |
| Net foreign currency gains /(losses) | 17 | | (22 | ) |
| Net fair value change on borrowings and other
financial liabilities | (9 | ) | (6 | ) |
| Total | 2,050 | | 9,905 | |

The decrease of the net fair value change on for account of policyholder financial assets at FVTPL in Q1 2016 compared to Q1 2015 is mainly driven by equity markets and interest rates movements.

Net fair value change on for accounts of policyholder financial assets at FVTPL is offset by amounts in the Claims and benefits line reported in note 7 - Benefits and expenses.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 21

7. Benefits and expenses

EUR millions — Claims and benefits Q1 2016 — 10,041 Q1 2015 — 18,338
Employee expenses 596 562
Administration expenses 311 297
Deferred expenses (323 ) (413 )
Amortization charges 277 343
Total 10,901 19,127

The following table provides an analysis of “claims and benefits”:

EUR millions — Benefits and claims paid life Q1 2016 — 4,711 Q1 2015 — 5,778
Benefits and claims paid non-life 538 514
Change in valuation of liabilities for insurance contracts 3,000 10,095
Change in valuation of liabilities for investment contracts 284 408
Other (5 ) (21 )
Policyholder claims and benefits 8,527 16,774
Premium paid to reinsurers 713 689
Profit sharing and rebates 7 8
Commissions 795 867
Total 10,041 18,338

The lines “change in valuation of liabilities for insurance contracts” and “change in valuation of liabilities for investment contracts” reflect changes in technical provisions resulting from fair value changes on for account of policyholder financial assets included in Results from financial transactions (note 6) of EUR 1,596 (2015 Q1: EUR 8,300). In addition, the line “change in valuation of liabilities for insurance contracts” includes changes in technical provisions for life insurance contracts of EUR 1,863 (2015 Q1: EUR 2,846).

Unaudited

Table of Contents

22 Condensed Consolidated Interim Financial Statements Q1 2016

8. Impairment charges/(reversals)

EUR millions Q1 2016 Q1 2015
Impairment charges / (reversals) comprise:
Impairment charges on financial assets, excluding receivables 1 41 18
Impairment reversals on financial assets, excluding receivables 1 (6 ) (5 )
Impact of the above impairments on the valuation of insurance assets and
liabilities 1 4 -
Impairment charges / (reversals) on non-financial
assets and receivables 1 -
Total 40 13
Impairment charges on financial assets, excluding receivables,
from:
Shares 10 2
Debt securities and money market instruments 28 3
Loans 3 12
Total 41 18
Impairment reversals on financial assets, excluding receivables,
from:
Debt securities and money market instruments (3 ) (3 )
Loans (4 ) (2 )
Total (6 ) (5 )

1 Impairment charges / (reversals) on financial assets, excluding receivables, are excluded from underlying earnings before tax for segment reporting (refer to note 3.1).

9. Intangible assets

EUR millions Mar. 31, 2016 Dec. 31, 2015
Goodwill 276 299
VOBA 1,403 1,472
Future servicing rights 65 57
Software 59 61
Other 12 12
Total intangible assets 1,815 1,901

Intangible assets, except for goodwill, are predominantly impacted by periodic amortization of balances and changes in exchange rates.

10. Investments

EUR millions Mar. 31, 2016 Dec. 31, 2015
Available-for-sale (AFS) 116,821 114,409
Loans 38,542 38,577
Financial assets at fair value through profit or
loss (FVTPL) 5,547 5,816
Financial assets, for general account, excluding derivatives 160,910 158,803
Investments in real estate 1,874 1,990
Total investments for general account,
excluding derivatives 162,784 160,792

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 23

Financial assets, for general account, excluding derivatives — EUR millions AFS FVTPL Loans Total
Shares 821 589 - 1,411
Debt securities 106,876 2,236 - 109,112
Money market and other short-term investments 7,882 321 - 8,203
Mortgages loans - - 33,192 33,192
Private loans - - 2,947 2,947
Deposits with financial institutions - - 207 207
Policy loans - - 2,079 2,079
Other 1,242 2,401 117 3,760
March 31, 2016 116,821 5,547 38,542 160,910
AFS FVTPL Loans Total
Shares 820 640 - 1,460
Debt securities 105,151 2,239 - 107,390
Money market and other short-term investments 7,141 303 - 7,444
Mortgages loans - - 33,214 33,214
Private loans - - 2,847 2,847
Deposits with financial institutions - - 106 106
Policy loans - - 2,201 2,201
Other 1,297 2,635 210 4,141
December 31, 2015 114,409 5,816 38,577 158,803

11. Investments for account of policyholders

EUR millions Mar. 31, 2016 Dec. 31, 2015
Shares 24,647 26,699
Debt securities 31,395 31,606
Money market and short-term investments 1,595 1,907
Deposits with financial institutions 1,555 1,222
Unconsolidated investment funds 128,197 134,845
Other 3,140 2,925
Total investments for account of policyholders at fair value through profit or
loss, excluding derivatives 190,529 199,204
Investment in real estate 758 1,022
Total investments for account of
policyholders 191,286 200,226

12. Derivatives

The movements in derivative balances mainly result from changes in interest rates during the period as well as purchases and disposals.

Unaudited

Table of Contents

24 Condensed Consolidated Interim Financial Statements Q1 2016

13. Fair value

The following tables provide an analysis of financial instruments recorded at fair value on a recurring basis by level of the fair value hierarchy:

Fair value hierarchy — EUR millions Level I Level II Level III Total
As at March 31, 2016
Financial assets carried at fair value
Available-for-sale investments
Shares 30 477 314 821
Debt securities 31,068 72,375 3,432 106,876
Money markets and other short-term instruments - 7,882 - 7,882
Other investments at fair value 26 358 858 1,242
Total
Available-for-sale investments 31,125 81,092 4,604 116,821
Fair value through profit or loss
Shares 225 364 - 589
Debt securities 18 2,212 6 2,236
Money markets and other short-term instruments - 321 - 321
Other investments at fair value 1 1,308 1,091 2,401
Investments for account of policyholders 1 115,761 73,178 1,590 190,529
Derivatives 19 16,861 409 17,288
Total Fair value
through profit or loss 116,024 94,244 3,095 213,364
Total financial assets at fair
value 147,149 175,337 7,699 330,185
Financial liabilities carried at fair value
Investment contracts for account of policyholders 2 16,391 22,376 131 38,899
Borrowings 3 - 600 - 600
Derivatives (17 ) 13,327 3,158 16,468
Total financial
liabilities at fair value 16,374 36,304 3,289 55,967
Fair value hierarchy
EUR millions Level I Level II Level III Total
As at December 31, 2015
Financial assets carried at fair value
Available-for-sale investments
Shares 29 498 293 820
Debt securities 28,701 72,307 4,144 105,151
Money markets and other short-term instruments - 7,141 - 7,141
Other investments at fair value 31 337 928 1,297
Total
Available-for-sale investments 28,761 80,283 5,365 114,409
Fair value through profit or loss
Shares 254 385 - 640
Debt securities 16 2,217 6 2,239
Money markets and other short-term instruments - 303 - 303
Other investments at fair value 2 1,368 1,265 2,635
Investments for account of policyholders 1 121,227 76,232 1,745 199,204
Derivatives 54 11,270 222 11,545
Total Fair value
through profit or loss 121,552 91,775 3,239 216,566
Total financial assets at fair
value 150,313 172,058 8,604 330,975
Financial liabilities carried at fair value
Investment contracts for account of policyholders 2 16,943 23,266 156 40,365
Borrowings 3 - 617 - 617
Derivatives 4 8,782 2,104 10,890
Total financial liabilities at fair
value 16,946 32,665 2,260 51,871

1 The investments for account of policyholders included in the table above represents only those investments carried at fair value through profit or loss.

2 The investment contracts for account of policyholders included in the table above represents only those investment contracts carried at fair value.

3 Total borrowings on the statement of financial position contain borrowings carried at amortized cost that are not included in the above schedule.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 25

Significant transfers between Level I, Level II and Level III

Aegon’s policy is to record transfers of assets and liabilities between Level I, Level II and Level III at their fair values as of the beginning of each reporting period.

The table below shows transfers between Level I and II for financial assets and financial liabilities recorded at fair value on a recurring basis during the three month period ended March 31, 2016.

Fair value transfers — EUR millions Q1 2016 Full Year 2015
Transfers Level I to Level II Transfers Level II to Level I Transfers Level I to Level II Transfers Level II to Level I
Financial assets carried at fair value
Available-for-sale investments
Debt securities 1 2 14 156
Total 1 2 14 156
Fair value through profit or loss
Shares - - - 40
Investments for account of
policyholders - 2 (3 ) 209
Total - 2 (3 ) 248
Total financial assets at fair
value 1 4 11 405
Financial liabilities carried at fair value
Investment contracts for account of
policyholders - - - 1
Total financial liabilities at fair
value - - - 1

Transfers are identified based on transaction volume and frequency, which are indicative of an active market.

Movements in Level III financial instruments measured at fair value

The following table summarizes the change of all assets and liabilities measured at estimated fair value on a recurring basis using significant unobservable inputs (‘Level III’), including realized and unrealized gains (losses) of all assets and liabilities and unrealized gains (losses) of all assets and liabilities still held at the end of the respective period.

| Roll forward of Level III financial instruments — EUR millions | January 1, 2016 | Total gains / losses in income statement 1 | Total gains / losses in OCI 2 | | Purchases | Sales | | Settlements | | Net exchange differences | | Reclassification | | Transfers from Level I and Level II | Transfers to Level I and Level II | | March 31, 2016 | Total unrealized gains and losses for the
period recorded in the P&L for instruments held at March 31, 2016 ³ | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Financial assets carried at fair value available-for-sale
investments | | | | | | | | | | | | | | | | | | | | |
| Shares | 293 | 3 | | (1 | ) | 44 | (17 | ) | - | | (8 | ) | - | | - | - | | 314 | - | |
| Debt securities | 4,144 | 5 | | 11 | | 61 | (37 | ) | (75 | ) | (71 | ) | - | | 82 | (688 | ) | 3,432 | - | |
| Other investments at fair value | 928 | (25 | ) | 17 | | 43 | (62 | ) | (1 | ) | (43 | ) | - | | - | - | | 858 | - | |
| | 5,365 | (18 | ) | 28 | | 149 | (117 | ) | (75 | ) | (122 | ) | - | | 82 | (688 | ) | 4,604 | - | |
| Fair value through profit or loss | | | | | | | | | | | | | | | | | | | | |
| Debt securities | 6 | - | | - | | - | - | | - | | - | | - | | - | - | | 6 | - | |
| Other investments at fair value | 1,265 | (39 | ) | - | | 16 | (32 | ) | - | | (55 | ) | - | | 93 | (157 | ) | 1,091 | (36 | ) |
| Investments for account of policyholders | 1,745 | (58 | ) | - | | 105 | (138 | ) | - | | (28 | ) | - | | - | (36 | ) | 1,590 | (60 | ) |
| Derivatives | 222 | (2 | ) | - | | - | 240 | | - | | (15 | ) | (36 | ) | - | - | | 409 | (1 | ) |
| | 3,239 | (100 | ) | - | | 121 | 70 | | - | | (98 | ) | (36 | ) | 93 | (193 | ) | 3,095 | (97 | ) |
| Financial liabilities carried at fair value | | | | | | | | | | | | | | | | | | | | |
| Investment contracts for account of policyholders | 156 | (19 | ) | - | | 3 | (2 | ) | - | | (5 | ) | - | | - | (2 | ) | 131 | (18 | ) |
| Derivatives | 2,104 | 1,303 | | - | | - | (160 | ) | - | | (53 | ) | (36 | ) | - | - | | 3,158 | 1,238 | |
| | 2,260 | 1,284 | | - | | 3 | (162 | ) | - | | (57 | ) | (36 | ) | - | (2 | ) | 3,289 | 1,219 | |

Unaudited

Table of Contents

26 Condensed Consolidated Interim Financial Statements Q1 2016

EUR millions
Financial assets carried at fair value available-for-sale
investments
Shares 280 32 30 92 (124 ) (33 ) 16 - - - 293 -
Debt securities 3,803 (2 ) 29 842 (367 ) (198 ) 212 - 182 (359 ) 4,144 -
Other investments at fair value 934 (206 ) 9 179 (72 ) (18 ) 102 - - - 928 -
5,018 (176 ) 69 1,113 (563 ) (249 ) 330 - 182 (359 ) 5,365 -
Fair value through profit or loss
Debt securities 17 - - - (2 ) - 2 - - (9 ) 6 -
Other investments at fair value 1,237 (20 ) - 179 (397 ) - 139 - 291 (162 ) 1,265 17
Investments for account of policyholders 1,956 126 - 486 (773 ) - 33 - - (83 ) 1,745 85
Derivatives 320 (173 ) - 12 48 - 15 - - - 222 (176 )
3,530 (67 ) - 677 (1,124 ) - 188 - 291 (255 ) 3,239 (74 )
Financial liabilities carried at fair value
Investment contracts for account of policyholders 165 3 - 12 (34 ) - 14 - - (5 ) 156 3
Derivatives 3,010 (925 ) - - (98 ) - 116 - - - 2,104 (972 )
3,175 (922 ) - 13 (131 ) - 131 - - (5 ) 2,260 (969 )

1 Includes impairments and movements related to fair value hedges. Gains and losses are recorded in the line item results from financial transactions of the income statement.

2 Total gains and losses are recorded in line items Gains/ (losses) on revaluation of available-for-sale investments and (Gains)/ losses transferred to the income statement on disposal and impairment of available-for-sale investment of the statement of other comprehensive income.

3 Total gains / (losses) for the period during which the financial instrument was in Level III.

During the first three months of 2016, Aegon transferred certain financial instruments from Level II to Level III of the fair value hierarchy. The reason for the change in level was that the market liquidity for these securities decreased, which led to a change in market observability of prices. Prior to transfer, the fair value for the Level II securities was determined using observable market transactions or corroborated broker quotes respectively for the same or similar instruments. The amount of assets and liabilities transferred to Level III was EUR 175 million (full year 2015: EUR 473 million). Since the transfer, all such assets have been valued using valuation models incorporating significant non market-observable inputs or uncorroborated broker quotes.

Similarly, during the first three months of 2016, Aegon transferred EUR 883 million (full year 2015: EUR 619 million) of financial instruments from Level III to other levels of the fair value hierarchy. The change in level was mainly the result of a return of activity in the market for these securities and that for these securities the fair value could be determined using observable market transactions or corroborated broker quotes for the same or similar instruments.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 27

The table below presents information about the significant unobservable inputs used for recurring fair value measurements for certain Level III financial instruments.

| Overview of significant unobservable inputs — EUR millions | Carrying amount March 31, 2016 | Valuation technique 1 | Significant unobservable input 2 | Range (weighted
average) |
| --- | --- | --- | --- | --- |
| Financial assets carried at fair value available-for-sale investments | | | | |
| Shares | 161 | Net asset value | n.a. | n.a. |
| | 153 | Other | n.a. | n.a. |
| | 314 | | | |
| Debt securities | | | | |
| | 2,909 | Broker quote | n.a. | n.a. |
| | 200 | Discounted cash flow | Credit spread | 1.58% - 4.44% (3.20%) |
| | 324 | Other | n.a. | n.a. |
| | 3,432 | | | |
| Other investments at fair value | | | | |
| Tax credit investments | 749 | Discounted cash flow | Discount rate | 6.9% |
| Investment funds | 69 | Net asset value | n.a. | n.a. |
| Other | 40 | Other | n.a. | n.a. |
| March 31, 2016 | 858 | | | |
| Fair value through profit or loss | | | | |
| Debt securities | 6 | Other | n.a. | n.a. |
| | 6 | | | |
| Other investments at fair value | | | | |
| Investment funds | 1,085 | Net asset value | n.a. | n.a. |
| Other | 5 | Other | n.a. | n.a. |
| | 1,091 | | | |
| Derivatives 3 | | | | |
| Longevity swap | 109 | Discounted cash flow | Mortality | |
| Other | 165 | Other | n.a. | n.a. |
| March 31, 2016 | 274 | | | |
| Financial liabilities carried at fair value | | | | |
| Derivatives | | | | |
| Embedded derivatives in insurance contracts | 3,150 | Discounted cash flow | Own Credit spread | 0.40% - 0.55% (0.46%) |
| Other | 8 | Other | n.a. | n.a. |
| Total financial liabilities at fair
value | 3,158 | | | |

1 Other in the table above (column Valuation technique) includes investments for which the fair value is uncorroborated and no broker quote is received.

2 Not applicable (n.a.) has been included when no significant unobservable assumption has been identified and used.

3 Investments for account of policyholders are excluded from the table above and from the disclosure regarding reasonably possible alternative assumptions. Policyholder assets, and their returns, belong to policyholders and do not impact Aegon’s net income or equity. The effect on total assets is offset by the effect on total liabilities. Derivatives exclude derivatives for account of policyholders amounting to EUR 135 million.

The description of Aegon’s methods of determining fair value is included in the consolidated financial statements for 2015. For reference purposes, the valuation techniques included in the table above are described in more detail on the following pages.

Shares

When available, Aegon uses quoted market prices in active markets to determine the fair value of its investments in shares. Fair values for unquoted shares are estimated using observations of the price/earnings or price/cash flow ratios of quoted companies considered comparable to the companies being valued. Valuations are adjusted to account for company-specific issues and the lack of liquidity inherent in an unquoted investment. Adjustments for illiquidity are generally based on available market evidence. In addition, a variety of other factors are reviewed by management, including, but not limited to, current operating performance, changes in market outlook and the third-party financing environment.

Available-for-sale shares include shares in a Federal Home Loan Bank (FHLB) for an amount of EUR 148 million (December 31, 2015: EUR 120 million) that are measured at par, which are reported as part of Other in the column Valuation technique. A FHLB has implicit financial support from the United States government. The redemption value of the shares is fixed at par and they can only be redeemed by the FHLB.

Unaudited

Table of Contents

28 Condensed Consolidated Interim Financial Statements Q1 2016

Debt securities

Aegon’s portfolio of debt securities can be subdivided in Residential mortgage-backed securities (RMBS), Commercial mortgage-backed securities (CMBS), Asset-backed securities (ABS), Corporate bonds and Sovereign debt. Below relevant details in the valuation methodology for these specific types of debt securities are described.

Valuations of RMBS, CMBS and ABS are monitored and reviewed on a monthly basis. Valuations per asset type are based on a pricing hierarchy which uses a waterfall approach that starts with market prices from indices and follows with third-party pricing services or brokers. The pricing hierarchy is dependent on the possibilities of corroboration of the market prices. If no market prices are available, Aegon uses internal models to determine fair value. Significant inputs included in the internal models are generally determined based on relative value analyses, which incorporate comparisons to instruments with similar collateral and risk profiles. Market standard models may be used to model the specific collateral composition and cash flow structure of each transaction.

Valuations of corporate bonds are monitored and reviewed on a monthly basis. The pricing hierarchy is dependent on the possibility of corroboration of market prices when available. If no market prices are available, valuations are determined by a discounted cash flow methodology using an internally calculated yield. The yield is comprised of a credit spread over a given benchmark. In all cases, the benchmark is an observable input. The credit spread contains both observable and unobservable inputs. Aegon starts by taking an observable credit spread from a similar bond of the given issuer, and then adjusts this spread based on unobservable inputs. These unobservable inputs may include subordination, liquidity and maturity differences. The weighted average credit spread used in valuation of corporate bonds has increased to 3.20% (December 31, 2015: 2.84%).

If available, Aegon uses quoted market prices in active markets to determine the fair value of its sovereign debt investments. If Aegon cannot make use of quoted market prices, market prices from indices or quotes from third-party pricing services or brokers are used.

Tax credit investments

The fair value of tax credit investments is determined by using a discounted cash flow valuation technique. This valuation technique takes into consideration projections of future capital contributions and distributions, as well as future tax credits and the tax benefits of future operating losses. The present value of these cash flows is calculated by applying a discount rate. In general, the discount rate is determined based on the cash outflows for the investments and the cash inflows from the tax credits/tax benefits (and the timing of those cash flows). These inputs are unobservable in the market place. The discount rate used in valuation of tax credit investments has decreased to 6.9% (December 31, 2015: 7.4%).

Investment funds

Investment funds include real estate funds, private equity funds and hedge funds. The fair values of investments held in non-quoted investment funds are determined by management after taking into consideration information provided by the fund managers. Aegon reviews the valuations each month and performs analytical procedures and trending analyses to ensure the fair values are appropriate.

Derivatives

Where quoted market prices are not available, other valuation techniques, such as option pricing or stochastic modeling, are applied. The valuation techniques incorporate all factors that a typical market participant would consider and are based on observable market data when available. Models are validated before they are used and calibrated to ensure that outputs reflect actual experience and comparable market prices.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 29

Fair values for exchange-traded derivatives, principally futures and certain options, are based on quoted market prices in active markets. Fair values for over-the-counter (OTC) derivatives represent amounts estimated to be received from or paid to a third party in settlement of these instruments. These derivatives are valued using pricing models based on the net present value of estimated future cash flows, directly observed prices from exchange-traded derivatives, other OTC trades, or external pricing services. Most valuations are derived from swap and volatility matrices, which are constructed for applicable indices and currencies using current market data from many industry standard sources. Option pricing is based on industry standard valuation models and current market levels, where applicable. The pricing of complex or illiquid instruments is based on internal models or an independent third party. For long-dated illiquid contracts, extrapolation methods are applied to observed market data in order to estimate inputs and assumptions that are not directly observable. To value OTC derivatives, management uses observed market information, other trades in the market and dealer prices.

Some OTC derivatives are so-called longevity derivatives. The payout of longevity derivatives is linked to publicly available mortality tables. The derivatives are measured using the present value of the best estimate of expected payouts of the derivative plus a risk margin. The best estimate of expected payouts is determined using best estimate of mortality developments. Aegon determined the risk margin by stressing the best estimate mortality developments to quantify the risk and applying a cost-of-capital methodology. The most significant unobservable input for these derivatives is the (projected) mortality development.

Aegon normally mitigates counterparty credit risk in derivative contracts by entering into collateral agreements where practical and in ISDA master netting agreements for each of the Group’s legal entities to facilitate Aegon’s right to offset credit risk exposure. Changes in the fair value of derivatives attributable to changes in counterparty credit risk were not significant.

Embedded derivatives in insurance contracts including guarantees

All bifurcated guarantees for minimum benefits in insurance and investment contracts are carried at fair value. These guarantees include guaranteed minimum withdrawal benefits (GMWB) in the United States, United Kingdom and Japan which are offered on some variable annuity products and are also assumed from a ceding company; minimum investment return guarantees on insurance products offered in the Netherlands, including group pension and traditional products; variable annuities sold in Europe and Japan.

Since the price of these guarantees is not quoted in any market, the fair values of these guarantees are based on discounted cash flows calculated as the present value of future expected payments to policyholders less the present value of assessed rider fees attributable to the guarantees. Given the complexity and long-term nature of these guarantees which are unlike instruments available in financial markets, their fair values are determined by using stochastic models under a variety of market return scenarios. A variety of factors are considered including credit spread, expected market rates of return, equity and interest rate volatility, correlations of market returns, discount rates and actuarial assumptions. The most significant unobservable factor is credit spread. The credit spread used in the valuations of embedded derivatives in insurance contracts increased to 0.46% (December 31, 2015: 0.33%).

The expected returns are based on risk-free rates. Aegon added a premium to reflect the credit spread as required. The credit spread is set by using the credit default swap (CDS) spreads of a reference portfolio of life insurance companies (including Aegon), adjusted to reflect the subordination of senior debt holders at the holding company level to the position of policyholders at the operating company level (who have priority in payments to other creditors). Aegon’s assumptions are set by region to reflect differences in the valuation of the guarantee embedded in the insurance contracts.

Since many of the assumptions are unobservable and are considered to be significant inputs to the liability valuation, the liability included in future policy benefits has been reflected within Level III of the fair value hierarchy.

Unaudited

Table of Contents

30 Condensed Consolidated Interim Financial Statements Q1 2016

Effect of reasonably possible alternative assumptions

The effect of changes in other unobservable inputs on fair value measurement were not significantly different than those that were applied to the consolidated financial statements as at and for the year ended December 31, 2015.

Fair value information about financial instruments not measured at fair value

The following table presents the carrying values and estimated fair values of financial assets and liabilities, excluding financial instruments which are carried at fair value on a recurring basis.

| Fair
value information about financial instruments not measured at fair value — EUR millions | Carrying amount March 31, 2016 | Total estimated fair value March 31, 2016 | Carrying amount December 31, 2015 | Total estimated fair value December 31, 2015 |
| --- | --- | --- | --- | --- |
| Assets | | | | |
| Mortgage loans - held at amortized cost | 33,192 | 37,951 | 33,214 | 37,648 |
| Private loans - held at amortized cost | 2,947 | 3,369 | 2,847 | 3,165 |
| Other loans - held at amortized
cost | 2,403 | 2,403 | 2,517 | 2,517 |
| Liabilities | | | | |
| Trust pass-through securities - held at amortized cost | 153 | 140 | 157 | 146 |
| Subordinated borrowings - held at amortized cost | 757 | 836 | 759 | 828 |
| Borrowings – held at amortized cost | 10,205 | 10,632 | 11,829 | 12,194 |
| Investment contracts - held at amortized
cost | 17,590 | 18,148 | 17,260 | 17,860 |

Financial instruments for which carrying value approximates fair value

Certain financial instruments that are not carried at fair value are carried at amounts that approximate fair value, due to their short-term nature and generally negligible credit risk. These instruments include cash and cash equivalents, short-term receivables and accrued interest receivable, short-term liabilities, and accrued liabilities. These instruments are not included in the table above.

14. Deferred expenses

EUR millions Mar. 31, 2016 Dec. 31, 2015
DPAC for insurance contracts and investment contracts with discretionary
participation features 9,781 10,457
Deferred cost of reinsurance 70 72
Deferred transaction costs for investment
management services 448 467
Total deferred expenses 10,299 10,997

15. Share capital

| EUR
millions | Mar. 31, 2016 | Dec. 31, 2015 | |
| --- | --- | --- | --- |
| Share capital - par value | 328 | 328 | |
| Share premium | 8,059 | 8,059 | |
| Total share capital | 8,387 | 8,387 | |
| Share capital - par value | | | |
| Balance at January 1 | 328 | 327 | |
| Issuance | - | - | |
| Share dividend | - | - | |
| Balance | 328 | 328 | |
| Share premium | | | |
| Balance at January 1 | 8,059 | 8,270 | |
| Share dividend | - | (211 | ) |
| Balance | 8,059 | 8,059 | |

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 31

Basic and diluted earnings per share

EUR millions Q1 2016 Q1 2015
Earnings per share (EUR per share)
Basic earnings per common share 0.05 0.12
Basic earnings per common share B - -
Diluted earnings per common share 0.05 0.12
Diluted earnings per common share
B - -
Earnings per share calculation
Net income / (loss) attributable to equity holders of Aegon N.V. 143 289
Coupons on other equity
instruments (35 ) (36 )
Earnings attributable to common shares and common shares B 109 253
Earnings attributable to common shareholders 108 251
Earnings attributable to common shareholders B 1 2
Weighted average number of common shares outstanding (in millions) 2,084 2,095
Weighted average number of common shares B
outstanding (in millions) 585 581

Dividend

Aegon will propose to the Annual General Meeting of Shareholders on May 20, 2016, absent unforeseen circumstances, to pay a final dividend for the year 2015 of EUR 0.13 per common share. After taking into account the interim dividend 2015 of EUR 0.12 per common share, this will result in a total 2015 dividend of EUR 0.25 per common share. Proposed final dividend for the year and proposed total 2015 dividend per common share B amount to 1/40th of the dividend paid on common shares.

Share buy back

As announced on January 13, 2016, during an update on Aegon’s strategic plans at its Analyst & Investor Conference, Aegon executed the first tranche of a share buyback program in which 41,082,683 common shares were repurchased. Between January 13, 2016 and March 31, 2016, these common shares were repurchased at an average price of EUR 4.8682 per share. It will be proposed to shareholders at the Annual General Meeting of Shareholders on May 20, 2016, to cancel all repurchased shares under this program. These common shares are being repurchased as part of a program to neutralize the dilutive effect of the cancellation of the preferred shares in 2013.

16. Borrowings

EUR millions — Capital funding 1,936 2,015
Operational funding 8,869 10,430
Total borrowings 10,806 12,445

Included in borrowings is EUR 600 million relating to borrowings measured at fair value (December 31, 2015: EUR 617 million).

Operational funding

During Q1 2016, Aegon redeemed EUR 450 million of ECB LTRO and repurchased the mortgage loans from SAECURE 9 and SAECURE 10 for EUR 1,658 million. In addition, Aegon entered into a USD 975 million new liquidity program from the Federal Home Loan Bank.

Unaudited

Table of Contents

32 Condensed Consolidated Interim Financial Statements Q1 2016

17. Commitments and contingencies

There have been no material changes in contingent assets and liabilities to those reported in the 2015 consolidated financial statements of Aegon.

18. Acquisitions / divestments

On January 18, 2016 Aegon Nederland N.V. signed an agreement to sell its commercial non-life insurance business, which includes the proxy and co-insurance run-off portfolios. The transaction is subject to approval by the Dutch Central Bank (De Nederlandsche Bank) and the Dutch Authority for Consumers and Markets (Autoriteit Consument & Markt). This sale is expected to be completed before July 1, 2016. This business continues to be part of Aegon’s reported numbers, until the transaction has been completed.

19. Events after the balance sheet date

On January 13, 2016, Aegon announced and started its EUR 400 million share buyback program to neutralize the dilutive effect of the cancellation of the preferred shares in 2013. The first tranche of EUR 200 million was completed on March 31, 2016 through the repurchase of 41.1 million shares. The second tranche of EUR 200 million was announced and started on April 1, 2016.

On April 11, 2016, Aegon announced the sale of two thirds of its UK annuity portfolio to Rothesay Life. Under the terms of the agreement, Aegon will reinsure GBP 6 billion of liabilities to Rothesay Life, followed by a Part VII transfer, which is subject to court approval. The reinsurance transaction is expected to result in an IFRS loss of approximately GBP 30 million (EUR 37 million) to be reported in the second quarter of 2016.

On May 3, 2016, Aegon announced it will buy BlackRock’s UK defined contribution (DC) platform and administration business. Through the agreement, Aegon will acquire approximately GBP 12 billion (EUR 15.2 billion) of assets and 350,000 customers from BlackRock, which serves institiutional and retail clients. The transaction is subject to closing conditions and a Part VII transfer of the underlying assets and liabilities to Aegon, which is subject to regulatory and court approval.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016 33

Disclaimers

Cautionary note regarding non-IFRS measures

This document includes the following non-IFRS financial measures: underlying earnings before tax, income tax and income before tax. These non-IFRS measures are calculated by consolidating on a proportionate basis Aegon’s joint ventures and associated companies. The reconciliation of these measures to the most comparable IFRS measure is provided in note 3 ‘Segment information’ of Aegon’s Condensed Consolidated Interim Financial Statements. Aegon believes that these non-IFRS measures, together with the IFRS information, provide meaningful information about the underlying operating results of Aegon’s business including insight into the financial measures that senior management uses in managing the business.

Forward-looking statements

The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:

t Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom;

t Changes in the performance of financial markets, including emerging markets, such as with regard to:

– The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios;

– The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and

– The effects of declining creditworthiness of certain private sector securities and the resulting decline in the value of sovereign exposure that Aegon holds;

t Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;

t Consequences of a potential (partial) break-up of the euro or the potential exit of the United Kingdom and/or Greece from the European Union;

t The frequency and severity of insured loss events;

t Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products;

t Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;

t Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;

t Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;

t Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;

t Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;

t Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, the products Aegon sells, and the attractiveness of certain products to its consumers;

t Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates;

t Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII).

t Changes in customer behavior and public opinion in general related to, among other things, the type of products also Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;

t Acts of God, acts of terrorism, acts of war and pandemics;

t Changes in the policies of central banks and/or governments;

t Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;

t Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the premium writings, policy retention, profitability and liquidity of its insurance subsidiaries;

t The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;

t Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;

t As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, a computer system failure or security breach may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;

t Customer responsiveness to both new products and distribution channels;

t Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;

t Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results and shareholders’ equity;

t The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;

t Catastrophic events, either manmade or by nature, could result in material losses and significantly interrupt Aegon’s business; and

t Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess capital and leverage ratio management initiatives.

Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements Q1 2016

Corporate and shareholder information

Headquarters
Aegon N.V.
P.O. Box 85
2501 CB The Hague
The Netherlands
+ 31 (0) 70 344 32 10
aegon.com
Group Corporate Communications &
Investor Relations
Media relations
+ 31 (0) 70 344 89 56
[email protected]
Investor relations
+ 31 (0) 70 344 83 05
or 877 548 96 68 - toll free, USA only
i [email protected]

Publication dates quarterly results 2016 and 2017

August 11, 2016 Results second quarter 2016
November 10, 2016 Results third quarter 2016
February 17, 2017 Results fourth quarter 2016

Aegon’s Q1 2016 press release and Financial Supplement are available on aegon.com.

About Aegon

Aegon’s roots go back more than 170 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information: aegon.com.

Unaudited